Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 10:15:9-27.
doi: 10.2147/OPTO.S350185. eCollection 2023.

Artificial Tears: A Systematic Review

David A Semp  1 , Danielle Beeson  1 , Amy L Sheppard  1 , Debarun Dutta  1 , James S Wolffsohn  1
Affiliations
Review

Artificial Tears: A Systematic Review

David A Semp et al. Clin Optom (Auckl). .

Abstract

Artificial tears are the mainstay of dry eye disease management, but also have a role in corneal abrasion and wound healing, pain and inflammation management, conjunctivitis, keratitis, contact lens rewetting and removal, and foreign body removal. A systematic review of randomized controlled trials (PROSPERO registration CRD42022369619) comparing the efficacy of artificial tears in patients with dry eye to inform prescribing choices using Web of Science, PubMed and Medline databases identified 64 relevant articles. There is good evidence that artificial tears improve symptoms of dry eye disease within a month of regular use, applied about four times a day, but signs generally take several months to improve. Not all patients with dry eye disease benefit from artificial tears, so if there is no benefit over a month, alternative management should be considered. Combination formulations are more effective than single active ingredient artificial tears. Artificial tears containing polyethylene glycol are more effective than those containing carboxymethylcellulose/carmellose sodium and hydroxypropyl methylcellulose. Those classified as having evaporative dry eye disease, benefit from artificial tears with liposomes, especially of higher concentration. The data available is limited by the definition of dry eye disease applied in published studies being variable, as well as the disease severity examined and compliance with artificial tears being rarely quantified.

Keywords: artificial tears; comfort; contact lenses; dry eye.

PubMed Disclaimer

Conflict of interest statement

JSW is on the executive of the Tear Film and Ocular Surface Society and the Aston University Optometry Research Group have received research funding from Alcon, the Eye Doctor, Scope Ophthalmic and Thea Pharmaceuticals. No funding was received to conduct this review. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
PRISMA 2020 flow diagram of the systematic review search results.
See this image and copyright information in PMC

References

    1. Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocular Surface. 2017;15(3):575–628. doi:10.1016/j.jtos.2017.05.006 - DOI - PubMed
    1. Pucker AD, Ng SM, Nichols JJ. Over the counter (OTC) artificial tear drops for dry eye syndrome. Cochrane Database Syst Rev. 2016;2016(2):Cd009729. doi:10.1002/14651858.CD009729.pub2 - DOI - PMC - PubMed
    1. Essa L, Laughton D, Wolffsohn JS. Can the optimum artificial tear treatment for dry eye disease be predicted from presenting signs and symptoms? Contact Lens Anterior Eye. 2018;41(1):60–68. doi:10.1016/j.clae.2017.07.007 - DOI - PubMed
    1. Craig JP, Muntz A, Wang MTM, et al. Developing evidence-based guidance for the treatment of dry eye disease with artificial tear supplements: a six-month multicentre, double-masked randomised controlled trial. Ocular Surface. 2021;20:62–69. doi:10.1016/j.jtos.2020.12.006 - DOI - PubMed
    1. Hynnekleiv L, Magno M, Vernhardsdottir RR, et al. Hyaluronic acid in the treatment of dry eye disease. Acta Ophthalmol. 2022;100:844–860. doi:10.1111/aos.15159 - DOI - PMC - PubMed